X4 Pharmaceuticals, a company focused on improving the lives of people with rare hematology diseases, entered into a senior secured term loan facility of up to $150 million with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. The K2HV facility replaces a prior loan agreement and strengthens X4’s financial flexibility.
The first tranche of $80 million funded at closing and was used to repay in full all obligations, including $75 million of principal and related fees, under the company’s prior loan and security agreement, along with associated closing costs. An additional $70 million may be made available to X4 at the company’s request, subject to approval by K2HV and other conditions. The new K2HV facility provides a larger total facility size, a longer interest-only period and a 48-month maturity to support corporate activities, including the potential future commercial launch of mavorixafor in chronic neutropenia.
“Our partnership with K2 HealthVentures strengthens our capital position and gives us a solid financial foundation as we advance mavorixafor toward potential FDA approval and a commercial launch in chronic neutropenia,” David Kirske, chief financial officer of X4, said. “The new structure provides additional flexibility on more favorable terms and is aligned with our strategic priorities. We expect to reach several key milestones in the near term, including completing enrollment in our Phase 3 4WARD trial this year and reporting topline results in the first half of 2028. We are executing with focus, discipline and a clear line of sight to what matters most.”
Parag Shah, founding managing director and CEO of K2 HealthVentures, added, “We are pleased to partner with X4 Pharmaceuticals as it advances mavorixafor for the potential treatment of people living with rare hematology diseases. This financing reflects our strategy of serving as a long-term financing partner to innovative life sciences companies, and we look forward to supporting X4’s next phase of growth.”
